Compounds > ketoconazole

ketoconazole and dihydroergotamine

ketoconazole has been researched along with dihydroergotamine in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (12.50)18.2507
2000's3 (37.50)29.6817
2010's4 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dantzig, AH; Ekins, S; Kim, RB; Lan, LB; Leake, BF; Schuetz, EG; Schuetz, JD; Shepard, RL; Wikel, JH; Winter, MA; Wrighton, SA; Yasuda, K1
Furuya, K; Lan, LB; Sanglard, D; Schuetz, EG; Schuetz, JD; Yasuda, K1
Pratim Roy, P; Roy, K1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Kitada, M; Kiuchi, M; Nakamura, H; Nakasa, H; Ohmori, S; Ono, S; Tsutsui, M1
Chang, J; Dodick, D; Febbraro, S; Forst, A; Kellerman, D; Kori, S; Taylor, G; Thomas, T; Wutann, L1

Reviews

1 review(s) available for ketoconazole and dihydroergotamine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for ketoconazole and dihydroergotamine

ArticleYear
Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans.
    Cephalalgia : an international journal of headache, 2012, Volume: 32, Issue:2

    Topics: 14-alpha Demethylase Inhibitors; Administration, Inhalation; Adult; Chemistry, Pharmaceutical; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dihydroergotamine; Drug Interactions; Female; Humans; Ketoconazole; Male; Migraine Disorders; Vasoconstrictor Agents; Young Adult

2012

Other Studies

6 other study(ies) available for ketoconazole and dihydroergotamine

ArticleYear
Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.
    Molecular pharmacology, 2002, Volume: 61, Issue:5

    Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Ergonovine; Fluoxetine; Humans; Models, Molecular; Oxytocics; Protein Conformation; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship; Swine; Transfection; Vinblastine

2002
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
    The Journal of pharmacology and experimental therapeutics, 2002, Volume: 303, Issue:1

    Topics: Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Line; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dihydroergocryptine; Drug Interactions; Enzyme Inhibitors; Fluconazole; Humans; Mice; Mice, Knockout; Microsomes, Liver; Oxidoreductases, N-Demethylating; Recombinant Proteins; Reserpine; Swine; Tissue Distribution; Transfection; Vinblastine

2002
Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:7

    Topics: Algorithms; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Inhibitors; Factor Analysis, Statistical; Least-Squares Analysis; Linear Models; Models, Molecular; Neural Networks, Computer; Quantitative Structure-Activity Relationship; Reproducibility of Results

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data.
    European journal of clinical pharmacology, 1998, Volume: 54, Issue:2

    Topics: Anticonvulsants; Cyclosporine; Cytochrome P-450 Enzyme System; Dihydroergotamine; Drug Interactions; Humans; In Vitro Techniques; Isoxazoles; Itraconazole; Ketoconazole; Metabolic Clearance Rate; Miconazole; Triazolam; Zonisamide

1998